Downloads
-
Strategic Synthesis Of ASGCT And ASCO 2026
6/10/2026
The spring 2026 conference season made one thing obvious to those of us watching the data: the artisan era of ex vivo cellular manufacturing is finally receding.
-
Antibody Developability Analysis
6/5/2026
Evaluating the developability of therapeutic drug candidates early can help circumvent potential issues in late-stage development.
-
Biological And Functional Assays
6/5/2026
Curia provides a wide range of biochemical and cell-based bioassay workflows to support Discovery, Research & Development as well as cGxP therapeutic testing campaigns
-
From Gene Editing To NGS-Based T Cell Characterization
6/4/2026
Gene-edited T cells targeting PD-1 and TIGIT are redefining approaches to cancer therapy. Explore how cell engineering and integrated genomic workflows uncover critical insights into T cell function.
-
Enterprise Decision Support Software For Product Development
6/3/2026
The Only Software That Brings Together All of Your Team’s Process and Analytical Data in One Place
The future of science is collaborative
Modern pharmaceutical and chemical development teams must share information between many scientists, who are often spread across many locations, using different instruments.
Your data should be useful
More sources of data mean more spreadsheets, incompatible files, and time spent tracking down results. Information becomes siloed and data management gets in the way of research.
Make your data work for you with Luminata
Luminata lets your team store, search, map, process, and reuse all your chemical, analytical, and process data in one application. Streamline your chemical and pharmaceutical development with Luminata’s digital environment.
-
Streamline High Throughput Experimentation And Process Development
6/3/2026
Software for Automated, Digitalized Experimentation
Katalyst D2D® (Design-to-Decide) provides integrated experiment design, planning, execution, and analysis for high-throughput synthesis, process optimization, and preformulation studies. It helps scientists execute experiments more efficiently and connect data with decisions across the design-make-test-analyze (DMTA) cycle.
-
Assess the Safety Profile Of Pharmaceutical Impurities
6/3/2026
Predict Genotoxic & Carcinogenic Endpoints to Meet ICH M7(R2) Guidelines
ACD/Impurity Profiling Suite predicts a variety of toxicological endpoints to help you assess the genotoxic and carcinogenic potential of impurities and degradants. Developed through a collaborative agreement with the US Food and Drug Administration (FDA), the software can be used as part of your ICH M7(R2) workflow—to help prepare regulatory submissions and remain compliant.
- Determine the ICH M7(R2) classification for impurities and degradants
- Predict 21 toxicological endpoints from structure; for mechanisms of hazardous activity including:
- Mutagenicity (AMES test and other procaryote and eucaryote test systems)
- Clastogenicity
- Other DNA damage
- Carcinogenicity
- Endocrine disruption mechanisms
- Identify potentially hazardous structural fragments responsible for carcinogenic and genotoxic activity
- Gain insight into the possible mechanisms of toxic effects
- Assess the reliability of predictions
-
Software For Efficient, Comprehensive Metabolite Identification
6/3/2026
Accelerate metabolite identification with integrated analytics, predictive modeling, and automated data extraction. Visualize pathways, kinetics, and spectra in one place to improve confidence.
-
Streamline Experiments From Design To Decide
6/3/2026
Gain insight into how a connected approach to experimental design and data management helps reduce errors, accelerate iteration cycles, and unlock deeper insights.
-
Assess The Safety Of Pharmaceutical Impurities In Silico
6/3/2026
Advance impurity risk assessment with predictive modeling that clarifies toxicity mechanisms, strengthens regulatory arguments, and reduces experimental burden—helping teams make confident decisions.